From Nanoparticles To Patients With Mark van EldijK

Moving innovative science from the laboratory toward patients requires more than a promising discovery. It demands a clear understanding of how complex technologies behave, how they can be developed effectively, and what obstacles may emerge along the way.

Mark van Eldijk, Vice President of Science and Technology at Ardena, explores the evolving role of nanoparticles in advanced drug development and the practical considerations involved in turning sophisticated concepts into viable therapies. He examines the gap between scientific potential and real-world application, offering perspective on why translation can be difficult and what development teams must consider as technologies progress.

Listen to this episode of We Know Development™ for insights into the scientific and technical decisions that help shape the path from early innovation to patient impact.